At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Jul 1, 2026 at 08:00 ET
Evaxion announced a poster presentation at the International Herpesvirus Workshop 2026 for its preclinical CMV vaccine candidate EVX-V1. The data will guide final antigen selection for this next-generation candidate, but this is an early-stage, non-clinical event with no financial terms, regulatory action, or near-term value inflection, simply a routine scientific conference disclosure for a preclinical program.
- Poster presentation of new preclinical data for EVX-V1 at IHW 2026 in Montreal on July 12, 2026.
- EVX-V1 is a multi-component CMV vaccine candidate combining AI-discovered antigens with AI-optimized gB antigen.
- The data will guide final antigen selection for the vaccine candidate, no clinical timeline or regulatory milestone announced.
- No CMV vaccine has been approved to date; Evaxion remains at the preclinical stage for this program.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access